Results 81 to 90 of about 6,026 (204)

Acinetobacter radioresistens Bacteremia in Complicated Pneumonia. A Case Report and Literature Review

Clinical Case Reports, Volume 13, Issue 11, November 2025.
ABSTRACT Acinetobacter radioresistens, a ubiquitous non‐pathogen microorganism, is the source of the class D carbapenemase OXA‐23 being therefore a potential disseminator of resistance genes in Acinetobacter spp. At present few cases of human infections have been reported in the literature, all sensible to beta‐lactams.
Sara Campana, Francesco Giannone, Marco Torri, Carlo Rostagno   +3 more
wiley   +1 more source

Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020–2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program

Microbiology Spectrum
Cefiderocol and the β-lactam/β-lactamase inhibitor (BL-BLI) combinations ceftazidime-avibactam (CAZ-AVI), imipenem-relebactam (IMI-REL), and ceftolozane-tazobactam (TOL-TAZ) are recommended for the treatment of difficult-to-treat resistance (DTR ...
John H. Kimbrough, Maura H. Karr, Sean T. Nguyen, Boudewijn L. M. DeJonge, Chris Longshaw, Miki Takemura, Yoshinori Yamano, Mariana Castanheira, Rodrigo E. Mendes   +8 more
doaj   +1 more source

Detection of blaNDM‐1 and blaIMP‐1 Metallo‐β‐Lactamases in Meropenem‐Resistant Clinical Escherichia coli Isolates Using Modified Carbapenem Inactivation Method (mCIM) and PCR Techniques

Journal of Clinical Laboratory Analysis, Volume 39, Issue 21, November 2025.
This study examines the prevalence of blaNDM‐1 and blaIMP‐1 metallo‐β‐lactamase genes in meropenem‐resistant Escherichia coli isolates using mCIM and PCR. The results indicate a higher prevalence of blaNDM‐1 and suggest the presence of alternative resistance mechanisms in some strains, emphasizing the need for further research on antimicrobial ...
Mehdi Roshdi Maleki
wiley   +1 more source

In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies [PDF]

We described the emergence of ceftazidime/avibactam and cefiderocol cross-resistance in patients with KPC-producing Klebsiella pneumoniae infections. All strains with ceftazidime/avibactam and cefiderocol cross-resistance showed point mutations on KPC Ω ...
Amadesi S., Amedeo A., Gaibani P., Giannella M., Palombo M., Rinaldi M.   +5 more
core   +1 more source

Antibiotic Resistance: A Genetic and Physiological Perspective

MedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy, Ahmed H. El‐Sappah, Rong Guo, Xiaoling Luo, Shiyuan Deng, Meifang Du, Xiaohong Jian, Mohammed Bakeer, Zaixin Li, Zhi Zhang   +9 more
wiley   +1 more source

Elucidating the effect of iron acquisition systems in Klebsiella pneumoniae on susceptibility to the novel siderophore-cephalosporin cefiderocol [PDF]

, 2022
BACKGROUND: Cefiderocol (CFDC) is a novel siderophore-cephalosporin, effective against multidrug-resistant Gram-negative bacteria. As it has a siderophore side chain, it can utilize iron acquisition systems for penetration of the bacterial outer membrane.
Al-Marzooq, Farah, Collyns, Timothy, Daoud, Lana, Ghazawi, Akela, Moubareck, Carole Ayoub   +4 more
core   +1 more source

Experimental evolution of cefiderocol resistance in Pseudomonas aeruginosa

Heliyon
Cefiderocol is a novel and promising cephalosporin approved for treating severe infections caused by Gram-negative bacteria with limited therapeutic options. One of the primary targets of cefiderocol is Pseudomonas aeruginosa, a significant opportunistic
Igor Chebotar, Konstantin Kuleshov, Julia Bocharova, Nikolay Mayanskiy   +3 more
doaj   +1 more source

Discrepancies in Beta‐Lactam Antibiotics Cross‐Reactivity: Implications for Clinical Practice

Allergy, Volume 80, Issue 11, Page 3108-3114, November 2025.
Four studies previously published on beta‐lactam antibiotics cross‐reactivity were compared head‐to‐head. These studies covered 51 antibiotics, theoretically leading to 2550 potential recommendations regarding alternatives in case of specific allergies. The studies analysed different sets of beta‐lactam antibiotics.
Evelien Maria Hutten, Maja Bulatović Ćalasan, Jason Anthony Trubiano, Rick Gert‐Jan Pleijhuis, Ingrid Terreehorst   +4 more
wiley   +1 more source

Clonal lineage and biofilm growth shape cefiderocol activity in Acinetobacter baumannii from oncology patients

Frontiers in Cellular and Infection Microbiology
IntroductionAcinetobacter baumannii is a leading cause of healthcare-associated infections in immunocompromised patients and frequently exhibits multidrug resistance.
Ilaria Cavallo, Francesca Sivori, Mauro Truglio, Massimo Francalancia, Elva Abril, Giorgia Fabrizio, Sara Petrolo, Francesca Maione, Grazia Prignano, Arianna Mastrofrancesco, Fulvia Pimpinelli, Enea Gino Di Domenico   +11 more
doaj   +1 more source

Pharmacometrics as a tool to individualize treatment with anti-infective drugs [PDF]

The pharmacometrics models, such as population (Pop) pharmacokinetic (PK) models, were developed to explain the variability in PK parameters of anti-infective drugs including cefiderocol cefepime, rifampicin, and remdesivir, and to identify sources of ...
Bilal, Muhammad
core   +1 more source